105 related articles for article (PubMed ID: 23334483)
1. The SSG XVIII/AIO trial: results change the current adjuvant treatment recommendations for gastrointestinal stromal tumors.
Eisenberg BL
Am J Clin Oncol; 2013 Feb; 36(1):89-90. PubMed ID: 23334483
[TBL] [Abstract][Full Text] [Related]
2. Length of adjuvant imatinib therapy in GIST: weighing benefits, side effects and costs.
Dasanu CA
J Oncol Pharm Pract; 2012 Sep; 18(3):379-80. PubMed ID: 22801957
[TBL] [Abstract][Full Text] [Related]
3. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial.
Majer IM; Gelderblom H; van den Hout WB; Gray E; Verheggen BG
J Med Econ; 2013 Sep; 16(9):1106-19. PubMed ID: 23808902
[TBL] [Abstract][Full Text] [Related]
5. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
6. Managing GIST in the imatinib era: optimization of adjuvant therapy.
Trent JC; Subramanian MP
Expert Rev Anticancer Ther; 2014 Dec; 14(12):1445-59. PubMed ID: 25340579
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
[TBL] [Abstract][Full Text] [Related]
8. [New prospective on adjuvant treatment for gastrointestinal stromal tumors].
Pan ZZ; Wu XJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):212-5. PubMed ID: 23536337
[TBL] [Abstract][Full Text] [Related]
9. [Imatinib in the GIST therapy: ten years later].
Lopez M
Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more?
Hohenberger P
Lancet; 2009 Mar; 373(9669):1058-60. PubMed ID: 19303138
[No Abstract] [Full Text] [Related]
11. [Gastrointestinal stromal tumor (GIST): pathology in continuous development. Diagnostic-therapeutic strategies].
Sianesi M
Ann Ital Chir; 2009; 80(4):257-60. PubMed ID: 19967882
[No Abstract] [Full Text] [Related]
12. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group.
Blay JY; Le Cesne A; Ray-Coquard I; Bui B; Duffaud F; Delbaldo C; Adenis A; Viens P; Rios M; Bompas E; Cupissol D; Guillemet C; Kerbrat P; Fayette J; Chabaud S; Berthaud P; Perol D
J Clin Oncol; 2007 Mar; 25(9):1107-13. PubMed ID: 17369574
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant imatinib therapy for gastrointestinal stromal tumors.
Pisters PW; Colombo C
J Surg Oncol; 2011 Dec; 104(8):896-900. PubMed ID: 22069174
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials.
Patel S; Zalcberg JR
Eur J Cancer; 2008 Mar; 44(4):501-9. PubMed ID: 18234488
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort study.
Hatoum HT; Lin SJ; Sasane M; Trent JC
Curr Med Res Opin; 2012 May; 28(5):805-14. PubMed ID: 22506625
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
[TBL] [Abstract][Full Text] [Related]
18. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors.
Blay JY; Pérol D; Le Cesne A
Ann Oncol; 2012 Jul; 23(7):1659-65. PubMed ID: 22357253
[TBL] [Abstract][Full Text] [Related]
19. Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?
Hohenberger P
Nat Clin Pract Oncol; 2008 May; 5(5):240-1. PubMed ID: 18349856
[No Abstract] [Full Text] [Related]
20. [A step foward in the treatment of GIST].
Fattoruso SI; Lopez M
Clin Ter; 2008; 159(4):223-4. PubMed ID: 18776977
[No Abstract] [Full Text] [Related]
[Next] [New Search]
